Mereo BioPharma Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MREO?
Source: Globenewswire
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma for violations of securities laws, concerning securities purchases from June 5, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to discuss investor rights.
- Legal Proceedings: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.389
Low
0.50
Averages
2.08
High
5.00
Current: 0.389
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Mereo BioPharma Group PLC
- Class Action Initiated: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma Group PLC, covering all investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, to apply as lead plaintiff.
- False Statement Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for osteogenesis imperfecta, while concealing adverse facts that led to significant investor losses.
- Stock Collapse: Following a press release on December 29, 2025, revealing negative information related to the clinical trials, Mereo's stock price plummeted, severely undermining investor confidence and highlighting significant failures in the company's disclosure practices.
- Law Firm Background: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP boasts over 125 years of legal expertise in securities litigation, committed to pursuing justice for investors harmed by misrepresentations, showcasing its strong capability in protecting investor rights.
See More
Mereo BioPharma Faces Securities Litigation
- Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to possible false statements made during securities transactions from June 5, 2023, to December 26, 2025, impacting investor rights.
- Clinical Trial Failures: Mereo announced on December 29, 2025, that its two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting strong market disappointment in its product prospects.
- Investor Rights Protection: Faruqi & Faruqi reminds investors that April 6, 2026, is the deadline to apply to become the lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Disclosure Failures: The lawsuit alleges that Mereo and its executives failed to disclose the true status of its Phase 3 ORBIT and COSMIC programs, potentially leaving investors without critical information for decision-making, further raising concerns about corporate governance.
See More
Mereo BioPharma Faces Class Action Lawsuit Reminder
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma for violations of securities laws, concerning securities purchases from June 5, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to discuss investor rights.
- Legal Proceedings: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
Class Action Lawsuit Announced for Mereo BioPharma ADS Purchasers
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit for investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, aiming to seek compensation for affected investors, reflecting concerns over the company's future outlook.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab, despite the studies failing to meet primary endpoints, leading investors to purchase ADS at artificially inflated prices and incurring losses.
- Investor Rights Protection: Investors joining the class action can do so without any upfront costs and may receive compensation through a contingency fee arrangement, encouraging more affected investors to participate in protecting their rights.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, demonstrating its professional capability and resource advantages in handling similar cases.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that throughout the class period, defendants made overly optimistic statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers services on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Misleading Trial Results
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma on behalf of all investors who purchased ADSs between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, for lead plaintiff applications.
- False Statements Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the success likelihood of its Phase 3 clinical trials for setrusumab, claiming statistical significance would be achieved, while concealing that neither trial was on track to meet its primary endpoint.
- Stock Price Collapse: Following a December 29, 2025, disclosure that neither ORBIT nor COSMIC achieved statistical significance, Mereo's stock plummeted from $2.31 to $0.29 in a single trading session, representing an over 87% loss in shareholder value.
- Law Firm's Expertise: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP brings over 125 years of legal expertise in securities litigation, committed to seeking justice for investors harmed by misrepresented statements.
See More
Class Action Filed Against Mereo BioPharma Group PLC
- Class Action Initiated: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma Group PLC, covering all investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, to apply as lead plaintiff.
- False Statement Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for osteogenesis imperfecta, while concealing adverse facts that led to significant investor losses.
- Stock Collapse: Following a press release on December 29, 2025, revealing negative information related to the clinical trials, Mereo's stock price plummeted, severely undermining investor confidence and highlighting significant failures in the company's disclosure practices.
- Law Firm Background: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP boasts over 125 years of legal expertise in securities litigation, committed to pursuing justice for investors harmed by misrepresentations, showcasing its strong capability in protecting investor rights.
See More
Mereo BioPharma Faces Securities Litigation
- Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to possible false statements made during securities transactions from June 5, 2023, to December 26, 2025, impacting investor rights.
- Clinical Trial Failures: Mereo announced on December 29, 2025, that its two Phase 3 clinical trials failed to meet primary endpoints, causing its stock price to plummet by 87.64%, from $2.02 to $0.28 per share, reflecting strong market disappointment in its product prospects.
- Investor Rights Protection: Faruqi & Faruqi reminds investors that April 6, 2026, is the deadline to apply to become the lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Disclosure Failures: The lawsuit alleges that Mereo and its executives failed to disclose the true status of its Phase 3 ORBIT and COSMIC programs, potentially leaving investors without critical information for decision-making, further raising concerns about corporate governance.
See More
Mereo BioPharma Faces Class Action Lawsuit Reminder
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma for violations of securities laws, concerning securities purchases from June 5, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, resulting in investor losses when the truth emerged.
- Loss Recovery: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to discuss investor rights.
- Legal Proceedings: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
Class Action Lawsuit Announced for Mereo BioPharma ADS Purchasers
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit for investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, aiming to seek compensation for affected investors, reflecting concerns over the company's future outlook.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab, despite the studies failing to meet primary endpoints, leading investors to purchase ADS at artificially inflated prices and incurring losses.
- Investor Rights Protection: Investors joining the class action can do so without any upfront costs and may receive compensation through a contingency fee arrangement, encouraging more affected investors to participate in protecting their rights.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, demonstrating its professional capability and resource advantages in handling similar cases.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that throughout the class period, defendants made overly optimistic statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers services on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Misleading Trial Results
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma on behalf of all investors who purchased ADSs between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, for lead plaintiff applications.
- False Statements Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the success likelihood of its Phase 3 clinical trials for setrusumab, claiming statistical significance would be achieved, while concealing that neither trial was on track to meet its primary endpoint.
- Stock Price Collapse: Following a December 29, 2025, disclosure that neither ORBIT nor COSMIC achieved statistical significance, Mereo's stock plummeted from $2.31 to $0.29 in a single trading session, representing an over 87% loss in shareholder value.
- Law Firm's Expertise: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP brings over 125 years of legal expertise in securities litigation, committed to seeking justice for investors harmed by misrepresented statements.
See More
